In a recent decision, the Centers for Medicare and Medicaid Services have declined a proposal to expand Medicare coverage for ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

In recent years, GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have gained attention for their effectiveness in managing diabetes and supporting ...

What they don't tell you about Ozempic Weight-loss drugs like Ozempic and Wegovy have helped millions of Americans lose ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The proposal would have enabled more Americans to afford new medications in the GLP-1 class that have been shown to reduce weight.

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

STAT reports that the administration is planning on disrupting the fentanyl supply chain in order to reduce overdose deaths. The drug policy document is not public yet. More news is on South African ...

Dr. Michael Greger is famous for several books including “How Not to Die,” and for his website nutritionfacts.org. He ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...